1. FDA drug label, Effexor (venlafaxine extended-release capsules) approval 1997 [cited 2023 April 13]
2. Walton, Surrey M. Ph.D., Schumock, Glen T. Pharm.D., M.B.A., Lee, Ky-Van Ph.D., Alexander, G. Caleb M.D., M.S., Meltzer, David M.D., Ph.D.d, Stafford, Randall S. M.D., Ph.D. Developing Evidence-Based Research Priorities for Off-Label Drug Use. [cited March 23, 2022]
3. Walton SM, Schumock GT, Lee KV, Alexander GC, Meltzer D, Stafford RS. Prioritizing future research on off-label prescribing: results of a quantitative evaluation. Pharmacotherapy. 2008 Dec;28(12):1443-52. doi: 10.1592/phco.28.12.1443. PMID: 19025425; PMCID: PMC4406412. [cited 2023 April 13]
4. Schifano Fabrizio, Chiappini Stefania. Frontiers in Pharmacology. “Is There a Potential of Misuse for Venlafaxine and Bupropion?” [cited 2023 April 13]
5. Gabriel, M., & Sharma, V. (2017). Antidepressant discontinuation syndrome. CMAJ : Canadian Medical Association journal = journal de l’Association medicale canadienne, 189(21), E747. https://doi.org/10.1503/cmaj.160991 [cited 2023 April1 3]
6. Campagne D. M. (2005). Venlafaxine and serious withdrawal symptoms: warning to drivers. MedGenMed : Medscape general medicine, 7(3), 22. [cited 2023 April 13]
7. European Medicines Agency. “Background to the CPMP Position Paper on selective serotonin uptake inhibitors (SSRIs) and dependency/withdrawal reactions.” [published April 12, 200] [2023 April 13]
8. Fava, Maurizio M.D., Mulroy, Rosemarie B.A., Alpert, Jonathan M.D., Ph.D., Nierenberg, Andrew A. M.D., and Rosenbaum, Jerrold F. M.D.The American Journal of Psychiatry. “Emergence of Adverse Events Following Discontinuation of Treatment With Extended-Release Venlafaxine.” [published Dec 1, 1997] [cited 2023 April 13]
9. LaChance, L. R., & Ramsey, D. (2018). Antidepressant foods: An evidence-based nutrient profiling system for depression. World journal of psychiatry, 8(3), 97–104. https://doi.org/10.5498/wjp.v8.i3.97 [published online 2018 Sept 20] [cited 2023 April 13]
10. Diaper, A. M., Law, F. D., & Melichar, J. K. (2014). Pharmacological strategies for detoxification. British journal of clinical pharmacology, 77(2), 302–314. https://doi.org/10.1111/bcp.12245 [published online 2014 Jan 22] [cited 2023 April 13]
11. Apóstolo J, Bobrowicz-Campos E, Rodrigues M, Castro I, Cardoso D. The effectiveness of non-pharmacological interventions in older adults with depressive disorders: A systematic review. Int J Nurs Stud. 2016 Jun;58:59-70. doi: 10.1016/j.ijnurstu.2016.02.006. Epub 2016 Feb 17. PMID: 27087298. [cited 2023 April 13]
12. EUPATI publication Non-clinical development: Types of non clinical study published online [N.D.] [cited 2023 Dec 1]
13. Gautam M, Tripathi A, Deshmukh D, Gaur M. Cognitive Behavioral Therapy for Depression. Indian J Psychiatry. 2020 Jan;62(Suppl 2):S223-S229. doi: 10.4103/psychiatry.IndianJPsychiatry_772_19. Epub 2020 Jan 17. PMID: 32055065; PMCID: PMC7001356. [cited 2023 Dec 1]
14. Chang BH, Sommers E. Acupuncture and relaxation response for craving and anxiety reduction among military veterans in recovery from substance use disorder. Am J Addict. 2014 Mar-Apr;23(2):129-36. doi: 10.1111/j.1521-0391.2013.12079.x. Epub 2013 Aug 30. PMID: 25187049. [cited 2023 Dec 1]
15. Espí-López GV, Monzani L, Gabaldón-García E, Zurriaga R. The beneficial effects of therapeutic craniofacial massage on quality of life, mental health and menopausal symptoms and body image: A randomized controlled clinical trial. Complement Ther Med. 2020 Jun;51:102415. doi: 10.1016/j.ctim.2020.102415. Epub 2020 Apr 25. PMID: 32507432. [cited 2023 Dec 1]
16. Yeung A, Chan JSM, Cheung JC, Zou L. Qigong and Tai-Chi for Mood Regulation. Focus (Am Psychiatr Publ). 2018 Jan;16(1):40-47. doi: 10.1176/appi.focus.20170042. Epub 2018 Jan 24. PMID: 31975898; PMCID: PMC6519567. [cited 2023 Dec 1]
17. Cardenas-Iniguez C, Burnor E, Herting MM. Neurotoxicants, the Developing Brain, and Mental Health. Biol Psychiatry Glob Open Sci. 2022 Jul;2(3):223-232. doi: 10.1016/j.bpsgos.2022.05.002. Epub 2022 May 23. PMID: 35911498; PMCID: PMC9337627. [cited 2023 Dec 1]
18. National Research Council (US) Committee on Neurotoxicology and Models for Assessing Risk. Environmental Neurotoxicology. Washington (DC): National Academies Press (US); 1992. 1, Introduction: Defining the Problem of Neurotoxicity. Available from: https://www.ncbi.nlm.nih.gov/books/NBK234243/ [cited 2023 Dec 1]
19. Kern JK, Geier DA, Homme KG, King PG, Bjørklund G, Chirumbolo S, Geier MR. Developmental neurotoxicants and the vulnerable male brain: a systematic review of suspected neurotoxicants that disproportionally affect males. Acta Neurobiol Exp (Wars). 2017;77(4):269-296. PMID: 29369294. [cited 2023 Dec 1]
20. Nakao, M., Shirotsuki, K. & Sugaya, N. Cognitive–behavioral therapy for management of mental health and stress-related disorders: Recent advances in techniques and technologies. BioPsychoSocial Med 15, 16 (2021). https://doi.org/10.1186/s13030-021-00219-w [cited 2023 Dec 1]
21. Wang D, Wang Y, Wang Y, Li R, Zhou C. Impact of physical exercise on substance use disorders: a meta-analysis. PLoS One. 2014 Oct 16;9(10):e110728. doi: 10.1371/journal.pone.0110728. PMID: 25330437; PMCID: PMC4199732. [cited 2023 Dec 1]
22. Brown RP, Gerbarg PL. Sudarshan Kriya yogic breathing in the treatment of stress, anxiety, and depression: part I-neurophysiologic model. J Altern Complement Med. 2005 Feb;11(1):189-201. doi: 10.1089/acm.2005.11.189. Erratum in: J Altern Complement Med. 2005 Apr;11(2):383-4. PMID: 15750381. [cited 2023 Dec 1]
23. Clark, D. A., & Beck, A. T. (2010). Cognitive therapy of anxiety disorders: Science and practice. New York, NY: Guilford Press. [cited 2023 Dec 1]
24. Keng SL, Smoski MJ, Robins CJ. Effects of mindfulness on psychological health: a review of empirical studies. Clin Psychol Rev. 2011 Aug;31(6):1041-56. doi: 10.1016/j.cpr.2011.04.006. Epub 2011 May 13. PMID: 21802619; PMCID: PMC3679190. [cited 2023 Dec 1]
25. Lazar, S. W., Kerr, C. E., Wasserman, R. H., Gray, J. R., Greve, D. N., Treadway, M. T., McGarvey, M., Quinn, B. T., Dusek, J. A., Benson, H., Rauch, S. L., Moore, C. I., & Fischl, B. (2005). Meditation experience is associated with increased cortical thickness. Neuroreport, 16(17), 1893–1897. [cited 2023 Dec 1]
26. Michael P. Hengartner, Martin Plöderl; Newer-Generation Antidepressants and Suicide Risk in Randomized Controlled Trials: A Re-Analysis of the FDA Database. Psychother Psychosom 14 August 2019; 88 (4): 247–248. [cited 2024 April 24]
27. Sabljić V, Ružić K, Rakun R. Venlafaxine withdrawal syndrome. Psychiatr Danub. 2011 Mar;23(1):117-9. PMID: 21448114. [cited 2024 June 7]
28. Kora K, Kaplan P. Antidepresan ilaç kesimi ile tetiklenen hipomanik/manik kayma [Hypomania/mania induced by cessation of antidepressant drugs]. Turk Psikiyatri Derg. 2008 Fall;19(3):329-33. Turkish. PMID: 18791886. [cited 2024 June 7]